Johan Burisch © ECCO

Dear Y-ECCO Friends,

Did you enjoy the virtual ECCO Congress?

I personally found it very well organised and without major technical problems. And the programme was once again fantastic! As always, it was great to witness the many dedicated and brilliant researchers/physicians who work towards improving the care of IBD patients. But let’s hope that this is the last time that we cannot meet in person.

Bram Verstockt © ECCO

Dear Y-ECCO Friends,

Due to the pandemic, we unfortunately were unable to meet and interact physically in the usual way during our most recent Y-ECCO Basic Science Workshop. However, this is exactly what Y-ECCO is about: connecting people, colleagues and friends, clinicians and scientists in order to bring basic science from the bench to the bed, and back. Every year, the Y-ECCO Committee invites outstanding senior experts to give a state-of-the-art overview on hot topics in the IBD field. Furthermore, these top-notch speakers not only moderate the discussions that follow abstract presentations but also inspire and stimulate young researchers and clinician-scientists at the start of their careers. Although this year’s workshop was virtual, we succeeded in continuing our interactive format, with excellent talks and many questions via the virtual platform chat.

Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis

Sahu P, Kedia S, Vuyyuru SK et al.

Aliment Pharmacol Ther. 2021;53:568–76.

Homira Ayubi © Homira Ayubi

Introduction

Acute Severe Ulcerative Colitis (ASUC) is a medical emergency which affects about 25% of UC patients at least once in their lifetime [1]. Corticosteroids are the mainstay of treatment for ASUC; however, 30%–40% of patients do not respond and eventually need medical rescue therapy or surgery [2].Medical rescue therapy (in the form of ciclosporin or infliximab) can be costly and its use can be limited by side effects. Therefore, there is a need for safe and low-cost therapy which can augment the effect of corticosteroids to induce and maintain remission.

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Kennedy NA, Goodhand JR, Bewshea C, et al., Contributors to the CLARITY IBD study

Gut 2021;70:865–875

Jennifer Murray © Jennifer Murray

Introduction

Infection with the novel coronavirus SARS-CoV-2 leading to coronavirus disease-2019 (COVID-19) has a broad spectrum of clinical presentations and disease severity. A number of host and viral factors contribute to this heterogeneity in presentation and severity, including the host immune response [1]. Given that immune-mediated inflammatory diseases (IMIDs) including Inflammatory Bowel Disease (IBD), are characterised by immune dysregulation and use of biologic or immunosuppressive therapies, COVID-19 presents a particular challenge.

Central reading of ulcerative colitis clinical trial videos using neural networks

Gottlieb K, Requa J, Karnes W, et al.

Gastroenterology 2021;160:710–9.e2

Introduction

Endoscopic grading of the severity of Ulcerative Colitis (UC) is a critical component of disease assessment and particularly important for guiding therapy. Despite the availability of numerous scoring systems, such as the Mayo Endoscopic Score (eMS) and the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), widespread use in routine clinical practice is often limited, primarily due to inter-observer variability and lack of training for standardised use [1,2].

Charlotte Hedin © ECCO

Maria T Abreu, MD, is the Martin Kalser Endowed Chair in Gastroenterology, a Professor of Medicine, a Professor of Microbiology and Immunology, and Director of the Crohn's and Colitis Center at the University of Miami.

She is Council Chair of the American Gastroenterological Association (AGA) Institute Council and has served as Chair of the AGA’s Underrepresented Minorities Committee. She has also been appointed as Chair of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD).

She was interviewed via video link in March 2021.

Nuha Yassin © ECCO

Dear ECCO friends and colleagues,

Welcome to this issue of ECCO News and our new installment of the editorial officers' interview corner.

It gives me great pleasure to introduce you to Professor Alessandro Armuzzi, the new Secretary of ECCO.

Prof Armuzzi is the IBD lead and a professor of Gastroenterology at the Agostino Gemelli polyclinic, Catholic University Foundation in Rome, Italy. He has a very rich background and it was a delightful interview that I'm sure you'll enjoy. This time we wanted to put a face to the voice and background and have therefore recorded the interview for you to be able to watch at your leisure.

During the interview, Prof Armuzzi shares his personal and professional background as well as his vision and ambitions for his new role within ECCO. We hope that you enjoy our new format and this therapeutically energetic interview with our new Secretary.

Best Wishes

Nuha Yassin

Consultant Colorectal Surgeon

ECCO News Associate Editor

Serbia

Name of group: Serbian IBD Association - SIBDA 

Number of active members: 250
Number of meetings per year: 
Steering Committee meetings: 6 per year, 1 General Assembly per year
Educational meetings: 2 meetings/workshops annually
Patient relations meetings: 1 per year and on demand
President and Secretary: 
Aleksandra Sokic Milutinovic, President
Zoran Milenkovic, Secretary
National Representatives: Srdjan Djuranovic and Mirjana Cvetkovic
Joined ECCO in:  As an association in 2012; we have had National Representatives since the foundation of ECCO
Incidence of IBD in the country (if available): 
Not available at this time.

© Amgen

This engaging symposium, sponsored by Amgen, took place on July 8, 2021 as part of ECCO’21, and focussed on the role that artificial intelligence (AI) may play in the future management of patients with Inflammatory Bowel Disease (IBD). The symposium was well received and was viewed by over 400 delegates. First, Professor Gionata Fiorino highlighted the importance of early intervention in IBD and how AI approaches might be used to aid early diagnosis. Professor Edouard Louis subsequently discussed the future role that AI may play in the IBD treatment pathway, using examples from other therapy areas. Finally, Professor Walter Reinisch considered how personalised medicine approaches may transform the management of IBD in the future.

© Nestlé Health Science

Introduction

Franck Carbonnel - University Hospital of Kremlin Bicȇtre, France

There is an established association between a Western diet and the risk of Inflammatory Bowel Disease, including Crohn’s Disease (CD). Enteral nutrition has often been used to treat CD in children and adults. What evidence is there that a controlled diet can help to improve outcomes for CD patients?